Inovio

+$0.32 (+5.14%) Today
-$0.01 (-0.15%) As of 11:52 AM UTC after-hours

Why Robinhood?

You can buy or sell Inovio and other stocks, options, and ETFs commission-free!

About INO

Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline include VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP.

CEO
J. Joseph Kim
Employees
262
Headquarters
Plymouth Meeting, Pennsylvania
Founded
1983

INO Key Statistics

Market Cap
1.42B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
8.83M
High Today
$6.71
Low Today
$6.08
Open Price
$6.22
Volume
6.16M
52 Week High
$33.79
52 Week Low
$5.81

INO News

ReutersMay 10

Inovio to start global late-stage COVID-19 vaccine trial this summer

A woman holds a small bottle labelled with a "Coronavirus COVID-19 Vaccine" sticker in this illustration taken, October 30, 2020. REUTERS/Dado Ruvic/File Photo
MarketWatchMay 10

Inovio's stock is up after it shares new data from Phase 2 clinical trial for its COVID-19 vaccine candidate

Shares of Inovio Pharmaceuticals Inc. INO, +5.22% gained 8.0% in premarket trading on Monday after the company said its experimental COVID-19 vaccine was safe a
ReutersMay 10

Inovio says COVID-19 vaccine candidate safe, effective in clinical trial

Inovio Pharmaceuticals Inc (INO.O) said on Monday its COVID-19 vaccine candidate was safe, well-tolerated and produced immune response against the coronavirus i

INO Earnings

-$0.38
-$0.30
-$0.22
-$0.14
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Estimated
-$0.18 per share
Actual
-$0.27 per share
Replay Earnings Call

You May Also Like

RMR
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure